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Background: The pathogenesis of glioma is unclear. The disturbance of the apoptosis process plays a critical role
in glioma growth. Factors regulating the apoptosis process are to be further understood. This study aims to
investigate the role of protease activated receptor-2 (PAR2) in regulation the apoptosis process in glioma cells.
Results: The results showed that U87 cells and human glioma tissue expressed PAR2. Exposure to tryptase, or the
PAR2 active peptide, increased STAT3 phosphorylation in the radiated U87 cells, reduced U87 cell apoptosis,
suppressed the expression of p53 in U87 cells.
Conclusions: Activation of PAR2 can reduce the radiated U87 cell apoptosis via modulating the expression of p53.
The results implicate that PAR2 may be a novel therapeutic target in the treatment of glioma.
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Malignant gliomas are the most common and aggres-
sive adult brain tumors including anaplastic glioma and
glioblastoma multiforme; the clinical outcomes are very
poor; it is associated with a life expectancy of less than
two years in general. The pathogenesis of glioma is un-
clear. Thus, it is urgent to understand the pathogenesis
and find novel therapeutic targets for the treatment of
glioma [1,2].
Apoptosis is a process of programed cell death. Unlike
necrosis, apoptosis produces cell fragments called apop-
totic bodies that phagocytic cells are able to engulf and
quickly removed before the contents of the cell can spill
out onto surrounding cells and cause damage [3]. Under
physiological conditions, apoptosis is tightly regulated by
a number of factors, such as the signal transducer and
activator of transcription 3 (STAT3), which inhibits
apoptosis via suppressing p53 expression; the latter is a
tumor suppressor protein [4]. In addition to its impor-
tance as a biological phenomenon, defective apoptotic
processes have been implicated in an extensive variety
of diseases. Excessive apoptosis causes atrophy, de-
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reproduction in any medium, provided the ordiabetes [5], whereas an insufficient amount of apoptosis
results in uncontrolled cell growth, such as cancer [6]; the
initiation mechanism remains to be further investigated.
Protease-activated receptor (PAR) 2 is a member of
the large family of 7-transmembrane receptors that cou-
ple to guanosine-nucleotide-binding proteins. It is acti-
vated by trypsin. PAR2 can be activated by proteolytic
cleavage of its extracellular amino terminus. The new
amino terminus functions as a tethered ligand and acti-
vates the receptor [7]. Recent reports suggest that PAR2
is involved in the regulation of apoptosis [8]. Since de-
fective of apoptosis plays a crucial role in the patho-
genesis of cancer, we hypothesized that PAR2 might be
involved in the regulation of glioma cell apoptosis. To
test the hypothesis, using a glioma cell line, the U87
cells, as a study model, we observed that U87 cells ex-
pressed PAR2. Tryptase activated PAR2 to reduce U87
cell apoptosis by suppressing STAT3 phosphorylation
and regulating the levels of p53 in U87 cells.
Methods
Reagents
Antibodies of PAR2, STAT3, p53, and a STAT3 shRNA
kit were purchased from Santa Cruz Biotech (Shanghai,
China). Reagents for quantitative real time RT-PCR
(qRT-PCR) and Western blotting were purchased from In-
vitrogen (Shanghai, China). An annexin V kit and tryptase. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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The active PAR2 peptide and control peptide were pur-
chased from Alibaba Biotech (Hangzhou, China).
Cell culture
Glioma cell line, U87 cell, was purchased from ATCC.
U87 cells were cultured in DMEM medium supple-
mented with 10% fetal bovine serum, 2 mM glutamine,
200 U penicillin/ml, 0.2 g/ml streptomycin at 37°C.
Human glioma tissue collection
Surgically removed glioma tissue was collected from 3
patients (1 male, 2 females). The marginal normal tissue
was collected using as the normal control tissue. The gli-
oma tissue and normal tissue were proved by a patholo-
gist. The using human tissue in the present study was
approved by the Human Research Ethic Committee at
Three Gorges University. An informed, written consent
was obtained from each patient.
Irradiation
U87 cells were irradiated with a medical linear accelera-
tor (Varian Linear Accelerator models 2100C (/D), Varian
Medical Systems, Palo Alto, CA, USA) at 500 cGy/min;
the irradiation was continued until 8Gy as described
previously [9]. Control cells were unirradiated. 6-8 h
after the irradiation, the cells were processed for fur-
ther experiments.
qRT-PCR
Total RNA was extracted from U87 cells with the TRIzol
reagents. cDNA was converted from the RNA with a re-
verse transcription kit. qPCR was performed with SYBR
supermix in a MiniOptcon real time PCR system. The
Ct values were analyzed using the 2ΔΔCT method. The
target gene expression was normalized to the percent-
age of β-actin. The primers using in the present study
include: PAR2, forward, tgctagcagcctctctctcc; reverse,




Total proteins were extracted from the U87 cells and
separated on SDS-PAGE (sodium dodecyl sulfate poly-
acrylamide gel electrophoresis), and transferred onto a
nitrocellulose membrane; the membrane was blocked
with 5% skim milk for 30 min, incubated with the first
antibodies (100 ng-200 ng/ml) overnight at 4°C, and fol-
lowed by incubating with the secondary antibodies for
1 h. The membranes were washed with TBST (Tris buf-
fered saline-Triton X-100) after each incubation. The
immune complexes were developed with the enhancedluminol-based chemiluminescent substrate. The results
were recorded with X films.
Flow cytometry
Apoptosis of U87 cells was assessed by flow cytometry.
The live cells were stained with propidium iodide (PI)
and annexin V kit. The PI+ cells were gated out first;
the remaining cells were assessed to determine the fre-
quency of annexin V+ cells.
RNA interference (RNAi)
The STAT3 gene or PAR2 gene was knocked down in
U87 cells with commercial RNAi reagent kits following
the manufacturer’s instructions. The peak value of the
STAT3 or PAR2 knockdown was reached in 6-8 days
after the transduction.
Statistics
The data were presented as mean ± SD. Differences be-
tween groups were determined by Student t test. P < 0.05
was set as a significant criterion.
Results
Glioma cells express PAR2
We firstly assessed the expression of PAR2 in the glioma
tissue and glioma cell line, the U87 cells. As shown by
qRT-PCR and Western blotting, the expression of PAR2
was detected in U87 cells and glioma tissue at both
mRNA levels and protein levels. Much less PAR2 levels
were detected in the normal brain tissue (Figure 1).
Tryptase reduces radiation-induced U87 cell apoptosis
Mast cells are associated with cancer growth [10]. Tryp-
tase is one of the major chemical mediators of mast
cells; it cleaves PAR2 to activate the PAR2-bearing cells.
We postulate that tryptase activates U87 cells and influ-
ences the process of apoptosis induced by other factors
such as radiation. Thus, we treated U87 cells with radi-
ation in the presence or absence of tryptase or the PAR2
active peptide. As shown by flow cytometry data, about
4% apoptotic cells were detected in naïve U87 cells; after
radiation, the apoptotic U87 cells reached 56%, which
was abolished by the presence of tryptase or the PAR2
active peptide in the culture (Figure 2).
Tryptase suppresses radiation-induced STAT3
phosphorylation in U87 cells
STAT3 is involved in cancer growth [11]. Based on the
data of Figures 1 and 2, we infer that STAT3 is involved
in the inhibition of the radiation-induced U87 cell apop-
tosis in the presence of tryptase. Thus, we treated U87
cells with the same procedures of Figure 2. The results
showed that the STAT3 phosphorylation was detected
in naïve U87 cells, which was markedly suppressed by
Figure 1 Expression of PAR2 is increased in glioam cells. Total RNA and proteins were extracted from surgically removed glioma tissue
(3 patients), the marginal normal tissue and U87 cells; the samples were analyzed by qRT-PCR and Western blotting. A, the bars indicate the
mRNA levels of PAR2 (mean ± SD; *, p < 0.01, compared with normal tissue). B, the immune blots indicate the protein levels of PAR2. The data
represent 3 separate experiments.
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peptide significantly suppressed the phosphorylation of
STAT3, which was abolished by silencing the PAR2 gene
by RNAi (Figure 3). The results indicate that tryptase
can repress the phosphorylation of STAT3 in U87 cells.
Tryptase alters the expression of p53 in radiated U87
cells
P53 protein is an important molecule in the process of
apoptosis. Whether tryptase regulates the expression of
p53 in U87 cells, thus regulate the apoptosis of U87
cells, is unclear. We next assessed the levels of p53 inFigure 2 Tryptase inhibits U87 cell apoptosis. The treatment of U87 cel
treated with radiation (8Gy) in the culture. Dose of tryptase (control peptid
of PI+ U87 cells or/and Annexin V+ cells, which are summarized in B. PAR2d
with control shRNA. C, the PAR2 gene knockdown results. *, p < 0.01, comp
experiments.radiated U87 cells after stimulating by tryptase. The re-
sults showed that tryptase or the active PAR2 peptide
markedly suppressed the levels of p53 in U87 cells. To
further test the role of STAT3 in the tryptase-regulated
p53 expression in U87 cells, a batch of U87 cells were
knocked down the gene of STAT3, treated with radiation
and exposed to tryptase in the culture. Indeed, the ex-
pression of p53 was un-affected, similar to the saline
group or the PAR2-null U87 cells (Figure 4). The results
implicate that tryptase alters the apoptosis rate in radiated
U87 cells via regulating the expression of p53; STAT3
plays an important role in the process.ls is denoted above each dot plot panel. Radiation: U87 cells were
e and active peptide): 10 μg/ml. A, the dot plots indicat the frequency
: U87 cells with the PAR2 gene knockdown. cshRNA: U87 cells treated
ared with group A7 (mean ± SD). The data are from 3 separate
Figure 3 Tryptase increases STAT3 phosphorylation in radiated U87 cells. A, the treatment of radiated U87 cells is denoted below the
immune blots. B, the bars indicate the blot density of panel A. *, p < 0.01, compared with naïve U87 cells. PAR2d: PAR2-deficient U87 cells.
cshRNA: Control shRNA. The data represent 3 separate experiments.
Luo et al. Journal of Biomedical Science 2014, 21:25 Page 4 of 6
http://www.jbiomedsci.com/content/21/1/25Discussion and conclusions
The present study revealed that the glioma cell line, U87
cells, and human glioma tissue, expressed high levels of
PAR2. Upon exposure to tryptase, the radiation-induced
U87 cell apoptosis was reduced, the phosphorylation
of STAT3 was increased, p53 levels in U87 cells was
suppressed.
In line with published data [12], we observed that the
frequency of apoptotic U87 cells was increased after ir-
radiation. Apoptosis is a physiological phenomenon. The
significance of apoptosis is to remove senescent cells
[13] and the over functional cells, such as activated T
cells (a phenomenon designated the activation induced
cell death) [14]. Deregulation of apoptosis is associated
with the pathogenesis of a number of disorders, such as
tumor cell growth [15]. One of the novel findings of the
present study is that the expression of PAR2 is higher inFigure 4 Tryptase regulates expression of p53 in U87 cells. STAT3-suff
of tryptase or active PAR2 peptides for 48 h. The cells were analyzed for th
A, the bars indicate the mRNA levels of p53 (mean ± SD; *, p < 0.01, comp
of p53. C, the STAT3 gene knockdown results. The data represent 3 separate e
U87 cells. cshRNA: Radiated U87 cells were treated with control shRNA. The dU87 cells and human glioma tissue than normal brain
tissue; activation of PAR2 by exposing to tryptase or the
active PAR2 peptide can suppress the radiation-induced
U87 cell apoptosis. The results implicate that activa-
tion of PAR2 can dirsturb the radiation-induced U87
cell apoptosis.
Published data indicate that mast cells are residential
cells in the brain [16], such as in the thalamus, entorhi-
nal cortex, hippocampus and the leptomeninges [17-19].
Radiation stimulation is one of the factors inducing mast
cell activation [20]. Upon activation, mast cells release
mediators in a piecemeal fasion or anaphylactic fasion
[21,22]. The released tryptase may contact the body cells
to regulate the apoptotic process. Tryptase is one of the
major chemical mediators of mast cells. Previous reports
indicate a close association between mast cells and can-
cers. Ma et al suggest that dynamic mast cell-stromalicient or deficient U87 cells were cultured and radiated in the presence
e expression of p53 by qRT-PCR and Western blotting respectively.
ared with naive group). B, the immune blots indicate the protein levels
xperiments. STAT3d: STAT3 deficient U87 cells. PAR2d: PAR2-deficinet
ata represent 3 separate experiments.
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[23]. Khan et al indicate that mast cells are associated
in the pathogenesis of colitis-induced colon cancer [24].
Together with the present data, mast cell-derived tryptase
may contribute to the pathogenesis of cancer by disturb-
ing the process of apoptosis in the body cells. To approve
the inference, further experiments are needed.
STAT3 is an important mediator of tumor cell sur-
vival, growth, and invasion in a large group of glioma
[25]. Hu et al indicate that STAT3 has a crucial role in
cervical cancer progression, metastasis and develop to
anti-cancer therapies [26]. Carbajo-Pescador et al. pro-
pose that blocking STAT3 has the therapeutic poten-
tial in malignant tumors [27]. The phosphorylation of
STAT3 can inhibit p53 expression, or the inhibition of
STAT3 induces p53 accumulation [4]. Our data have
enriched the knowledge in this axis of STAT3-p53-
cancer by providing evidence that tryptase can increase
the phosphorylation of STAT3, so as to suppress the ex-
pression of p53. Mast cells regularly distribute all over
the body of both healthy person and patients with cancer,
and can be activated to release tryptase by a large number
of events, such as allergy [28], exposure to microbial
products [29] and radiation [30]. The radiation resistance
of cancer is a common syndrome in the treatment of
cancer; the pathogenesis is not fully understood. The
present data provide evidence that mast cell-derived
tryptase may be involved in the radiation resistance by
modulating STAT3 phosphorylation and p53 expression
in cancer cells. To prove the inference, further investiga-
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